Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients

[1]  M. Sanz,et al.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. , 2010, Blood.

[2]  M. Tormo,et al.  Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy , 2010, Haematologica.

[3]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[4]  H. Dombret,et al.  Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Esteve,et al.  Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. , 2008, Blood.

[6]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[7]  T. Naoe,et al.  Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome , 2007, European journal of haematology.

[8]  L. Escoda,et al.  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. , 2003, Blood.

[9]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Livak,et al.  Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. , 2003, Blood.

[11]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[12]  D. Grimwade,et al.  Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia , 2002, Leukemia.

[13]  M. Tallman,et al.  Acute promyelocytic leukemia: evolving therapeutic strategies. , 2002, Blood.

[14]  D. Scheinberg,et al.  Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. , 2001, Blood.

[15]  F. Mandelli,et al.  Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. , 2001, Seminars in hematology.

[16]  J. Miguel,et al.  Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. , 2000 .

[17]  W. Hiddemann,et al.  Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia , 2000, Leukemia.

[18]  J. Esteve,et al.  A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR-Positive Acute Promyelocytic Leukemia , 1999 .

[19]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[20]  F. Mandelli,et al.  Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial , 1998 .

[21]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[22]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[23]  P. Thall,et al.  Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[25]  T. Barbui,et al.  Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia , 1992, The Lancet.